We are live on ! Find out more
WGS icon

GeneDx Holdings

66.30 USD
-2.64
3.83%
At close Updated Oct 22, 11:15 AM EDT
1 day
-3.83%
5 days
-4.09%
1 month
-26.98%
3 months
5.91%
6 months
-5.06%
Year to date
-49.89%
1 year
-45.21%
5 years
-73.53%
10 years
-79.5%
 

About: GeneDx Holdings Corp focuses on genomics, creating the foundation for providing genomic information at scale and pioneering exome and genome sequencing for rare and ultra-rare genetic pediatric disorders. The company believes exome and genome testing will become the standard for diagnosing genetic disease, with the potential to transform healthcare from reactive to proactive. It aims to advance precision medicine by offering genetic diagnoses at the earliest moments, driving improved outcomes, and fueling discovery with genomic intelligence. Its operating segment mainly provides pediatric and rare disease diagnostics, focusing on whole exome and genome sequencing and, to a lesser extent, data and information services.

Employees: 1,300

News

Positive
Neutral
Negative
Sentiment 3-Months
Positive 6.5%
Neutral 93.5%
Negative 0%
Neutral
Business Wire
2 days ago
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx (Nasdaq: WGS), the leader in rare disease diagnosis and improving health through the power of genomic data, today announced plans to enhance its genome testing portfolio with long-read whole genome sequencing (lrWGS). Long-read sequencing analyzes longer stretches of DNA to identify complex genetic variation, including certain structural variants and repeat expansions that can go undetected by traditional short-read sequencing. With years of published.
GeneDx Expands Diagnostic Leadership with Long-Read Genome Sequencing, Advancing Rare Disease Diagnosis
Neutral
Business Wire
2 days ago
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx, the leader in rare disease diagnosis and improving health through the power of genomic data, today announced 27 accepted scientific abstracts at the American Society of Human Genetics (ASHG) 2026 Annual Meeting, highlighting how exome and genome sequencing are advancing scientific discovery, earlier diagnosis and more precise care. GeneDx research at ASHG 2026 highlights five areas: Scaling genomic interpretation with AI and machine learning: A GeneDx.
GeneDx Advances Clinical Adoption of Genomic Medicine with 27 Abstracts at ASHG 2026
Neutral
Business Wire
15 days ago
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026.
GeneDx Presents New Evidence Advancing Genomic Newborn Screening at ICoNS 2026
Neutral
Business Wire
20 days ago
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx introduces Easy Order at AAP 2026 to simplify genomic testing in everyday pediatric care.
GeneDx Introduces Easy Order at AAP 2026 to Simplify Genomic Testing in Everyday Pediatric Care
Neutral
Business Wire
1 month ago
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C.
GeneDx and Beren Therapeutics Launch NPC GenomeComplete to Improve Diagnosis of Niemann-Pick Disease Type C
Positive
Zacks Investment Research
1 month ago
3 Promising Genomics Stocks in the Spotlight in 2026
Genomics is reshaping healthcare, with WGS, NEO and NTLA advancing diagnostics and precision medicine.
3 Promising Genomics Stocks in the Spotlight in 2026
Neutral
Business Wire
1 month ago
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
GAITHERSBURG, Md.--(BUSINESS WIRE)--Katherine Stueland, CEO of GeneDx, has been named a 2026 Fierce 50 honoree for Health Equity.
GeneDx CEO Katherine Stueland Recognized as a 2026 Fierce 50 Honoree
Positive
Benzinga
1 month ago
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
Bears have piled into a familiar batch of volatile, heavily bet-against names, and nowhere is the wager bigger than on Venture Global, Inc. (NYSE:VG). More than 80% of its float is sold short, the steepest ratio on the market's current top-10 short-interest list, per Benzinga Pro data.
Short Sellers Are All-In on These 10 Stocks — Squeeze Watch List Inside
Neutral
Business Wire
1 month ago
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Seattle Children's show hospital-wide rapid genome sequencing accelerates accurate diagnosis and expands access to answers for children.
GeneDx Announces Transformative Study Supporting Hospital-Wide Adoption of Rapid Genomic Sequencing at Seattle Children's
Positive
Zacks Investment Research
2 months ago
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
GeneDx Holdings Corp. (WGS) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Can GENEDX HOLDINGS (WGS) Run Higher on Rising Earnings Estimates?
Price charts implemented using Lightweight Charts™